#USA #New York #Intrinsic Therapeutics #Barricaid #Amplify Surgical

Intrinsic Therapeutics Achieves Milestone with Barricaid Implant

Intrinsic Therapeutics, a pioneering company in medical technology, has announced a significant advancement in spinal surgery with the first implantation of the Barricaid® Annular Closure Device through an endoscopic approach. This innovative procedure took place at the Gramercy Surgery Center in New York under the expert hands of Dr. Daniel E. Choi, who is board-certified in orthopaedic spine surgery and trained at Harvard.

The Barricaid device is designed to significantly reduce the risk of reherniation in patients who have undergone lumbar discectomy, boasting an impressive 81% reduction in the need for reoperation. The successful implantation utilizing the new endoscopic method represents a notable shift in how spinal surgeries might be performed, enhancing the overall patient experience and outcomes.

Dr. Choi expressed his enthusiasm regarding the procedure, stating, "This novel endoscopic approach to spine surgery enabled direct visualization during the discectomy and implantation of Barricaid. I am grateful the two technologies allow for harmonious integration and see this as the next advancement in patient care." His words highlight the potential this technique has for improving surgical precision and patient safety.

The Chief Technology Officer of Intrinsic Therapeutics, Jacob Einhorn, remarked on the procedure, noting how seamlessly the dualPortal® endoscopic system integrated with the Barricaid device without necessitating any changes to instruments or procedural steps. This aspect is particularly beneficial for surgeons who favor endoscopic methods, as it not only helps maintain their existing discectomy outcomes but also mitigates the risks associated with spine surgery.

This milestone marks the first time the Barricaid device has been successfully implemented using Amplify Surgical's dualPortal system. CEO and Co-Founder of Amplify Surgical, Andy Choi, expressed his satisfaction, stating, "I am very pleased to see two unique products come together to help patients in ways never before demonstrated. By using dualPortal access, surgeons can broaden their selection of procedures performed in conjunction with an endoscope. We are extremely excited to add Barricaid to that list and look forward to continuing to support this cutting-edge combination."

About Barricaid

The Barricaid device is specialized technology aimed at preventing reherniation and the need for additional surgeries in patients suffering from large annular defects following lumbar discectomy. Over 12,000 patients have already benefited from this technology, which is backed by substantial clinical research across multiple patient populations. This includes two randomized controlled trials and six single-arm studies, with results demonstrating superior outcomes compared to conventional discectomy alone published in esteemed journals like JAMA, featuring five-year follow-up data.

In summary, Intrinsic Therapeutics' efforts in advancing spinal surgery with Barricaid via an endoscopic approach signifies a notable leap forward in patient care. With the integration of these technologies, there is much promise for improved surgical outcomes and a reduced risk profile for patients undergoing lumbar discectomy procedures. The field of spinal surgery is on the cusp of change, and with further advancements, patient quality of life can only be expected to improve dramatically.